α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
Identifieur interne : 000006 ( PubMed/Corpus ); précédent : 000005; suivant : 000007α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
Auteurs : Danhui Zhang ; Matthew Mcgregor ; Tanuja Bordia ; Xiomara A. Perez ; J Michael Mcintosh ; Michael W. Decker ; Maryka QuikSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.
Abstract
ABT-126 is a novel, safe, and well-tolerated α7 nicotinic receptor agonist in a Phase 2 Alzheimer's disease study. We tested the antidyskinetic effect of ABT-126 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys with moderate and more severe nigrostriatal damage.
DOI: 10.1002/mds.26453
PubMed: 26573698
Links to Exploration step
pubmed:26573698Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.</title><author><name sortKey="Zhang, Danhui" sort="Zhang, Danhui" uniqKey="Zhang D" first="Danhui" last="Zhang">Danhui Zhang</name><affiliation><nlm:affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mcgregor, Matthew" sort="Mcgregor, Matthew" uniqKey="Mcgregor M" first="Matthew" last="Mcgregor">Matthew Mcgregor</name><affiliation><nlm:affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Bordia, Tanuja" sort="Bordia, Tanuja" uniqKey="Bordia T" first="Tanuja" last="Bordia">Tanuja Bordia</name><affiliation><nlm:affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Perez, Xiomara A" sort="Perez, Xiomara A" uniqKey="Perez X" first="Xiomara A" last="Perez">Xiomara A. Perez</name><affiliation><nlm:affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mcintosh, J Michael" sort="Mcintosh, J Michael" uniqKey="Mcintosh J" first="J Michael" last="Mcintosh">J Michael Mcintosh</name><affiliation><nlm:affiliation>George E. Wahlen Veterans Affairs Medical Center and Departments of Psychiatry and Biology, University of Utah, Salt Lake City, Utah, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Decker, Michael W" sort="Decker, Michael W" uniqKey="Decker M" first="Michael W" last="Decker">Michael W. Decker</name><affiliation><nlm:affiliation>AbbVie, Inc, North Chicago, Illinois, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name><affiliation><nlm:affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="doi">10.1002/mds.26453</idno><idno type="RBID">pubmed:26573698</idno><idno type="pmid">26573698</idno><idno type="wicri:Area/PubMed/Corpus">000006</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.</title><author><name sortKey="Zhang, Danhui" sort="Zhang, Danhui" uniqKey="Zhang D" first="Danhui" last="Zhang">Danhui Zhang</name><affiliation><nlm:affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mcgregor, Matthew" sort="Mcgregor, Matthew" uniqKey="Mcgregor M" first="Matthew" last="Mcgregor">Matthew Mcgregor</name><affiliation><nlm:affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Bordia, Tanuja" sort="Bordia, Tanuja" uniqKey="Bordia T" first="Tanuja" last="Bordia">Tanuja Bordia</name><affiliation><nlm:affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Perez, Xiomara A" sort="Perez, Xiomara A" uniqKey="Perez X" first="Xiomara A" last="Perez">Xiomara A. Perez</name><affiliation><nlm:affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mcintosh, J Michael" sort="Mcintosh, J Michael" uniqKey="Mcintosh J" first="J Michael" last="Mcintosh">J Michael Mcintosh</name><affiliation><nlm:affiliation>George E. Wahlen Veterans Affairs Medical Center and Departments of Psychiatry and Biology, University of Utah, Salt Lake City, Utah, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Decker, Michael W" sort="Decker, Michael W" uniqKey="Decker M" first="Michael W" last="Decker">Michael W. Decker</name><affiliation><nlm:affiliation>AbbVie, Inc, North Chicago, Illinois, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Quik, Maryka" sort="Quik, Maryka" uniqKey="Quik M" first="Maryka" last="Quik">Maryka Quik</name><affiliation><nlm:affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">ABT-126 is a novel, safe, and well-tolerated α7 nicotinic receptor agonist in a Phase 2 Alzheimer's disease study. We tested the antidyskinetic effect of ABT-126 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys with moderate and more severe nigrostriatal damage.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">26573698</PMID><DateCreated><Year>2015</Year><Month>11</Month><Day>17</Day></DateCreated><DateRevised><Year>2015</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2015</Year><Month>Nov</Month><Day>17</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.</ArticleTitle><Pagination><MedlinePgn></MedlinePgn></Pagination><ELocationID EIdType="doi">10.1002/mds.26453</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">ABT-126 is a novel, safe, and well-tolerated α7 nicotinic receptor agonist in a Phase 2 Alzheimer's disease study. We tested the antidyskinetic effect of ABT-126 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys with moderate and more severe nigrostriatal damage.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Monkeys (n = 21, set 1) were lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-2×. When parkinsonian, they were gavaged with levodopa (10 mg/kg)/carbidopa (2.5 mg/kg) twice daily and dyskinesias rated. They were then given nicotine in drinking water (n = 5), or treated with vehicle (n = 6) or ABT-126 (n = 10) twice daily orally 30 min before levodopa. Set 1 was then re-lesioned 1 to 2 times for a total of 3 to 4 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections. The antidyskinetic effect of ABT-126, nicotine, and the β2* nicotinic receptor agonist ABT-894 was re-assessed. Another group of monkeys (n = 23, set 2) were lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine only 1× to 2×. They were treated with levodopa/carbidopa, administered the α7 agonist ABT-107 (n = 6), ABT-894 (n = 6), nicotine (n = 5), or vehicle (n = 6) and dyskinesias evaluated. All monkeys were euthanized and the dopamine transporter measured.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">With moderate nigrostriatal damage (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1×-2×), ABT-126 dose-dependently decreased dyskinesias (∼60%), with similar results seen with ABT-894 (∼60%) or nicotine (∼60%). With more severe damage (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 3-4×), ABT-126 and nicotine reduced dyskinesias, but ABT-894 did not. The dopamine transporter was 41% and 8.9% of control, with moderate and severe nigrostriatal damage, respectively. No drug modified parkinsonism.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The novel α7 nicotinic receptor drug ABT-126 reduced dyskinesias in monkeys with both moderate and severe nigrostriatal damage. ABT-126 may be useful to reduce dyskinesias in both early- and later-stage Parkinson's disease. © 2015 International Parkinson and Movement Disorder Society.</AbstractText><CopyrightInformation>© 2015 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList><Author><LastName>Zhang</LastName><ForeName>Danhui</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</Affiliation></AffiliationInfo></Author><Author><LastName>McGregor</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</Affiliation></AffiliationInfo></Author><Author><LastName>Bordia</LastName><ForeName>Tanuja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</Affiliation></AffiliationInfo></Author><Author><LastName>Perez</LastName><ForeName>Xiomara A</ForeName><Initials>XA</Initials><AffiliationInfo><Affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</Affiliation></AffiliationInfo></Author><Author><LastName>McIntosh</LastName><ForeName>J Michael</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>George E. Wahlen Veterans Affairs Medical Center and Departments of Psychiatry and Biology, University of Utah, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author><LastName>Decker</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>AbbVie, Inc, North Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author><LastName>Quik</LastName><ForeName>Maryka</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Health Sciences, SRI International, Menlo Park, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ENG</Language><GrantList><Grant><GrantID>R01 NS059910</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="">REVIEW</PublicationType><PublicationType UI="">JOURNAL ARTICLE</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ABT-126</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">dyskinesia</Keyword><Keyword MajorTopicYN="N">levodopa</Keyword><Keyword MajorTopicYN="N">nicotinic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26453</ArticleId><ArticleId IdType="pubmed">26573698</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000006 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000006 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26573698
|texte= α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26573698" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |